Selecta Biosciences (SELB) Misses Q4 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Selecta Biosciences Reports Fourth Quarter 2019 and Year-End Financial Results
March 12, 2020 8:00 AM EDT- Topline results from head-to-head COMPARE trial of SEL-212Â in chronic refractory gout expected in Q3 2020 -
- Received guidance from the FDA on SEL-212 Phase 3 clinical trial design; study to commence in 2H 2020 -
- Gene therapy program expected to enter the clinic by the end of 2020 -
- Company to host conference call today at 8:30 AM ET -
WATERTOWN,... More
